Sunday 18 October 2026
Export FATE’s income statement to Excel — free account
Fate Therapeutics, Inc.
FATE Healthcare Biotechnology
Fate Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 million, down 51.2% from fiscal 2024. In the quarter to June 2026, revenue grew 9.18%, EPS grew 13.8% and free cash flow grew 8.96%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.79
0.14
−7.25%
Follow FATE
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
3 | 2 | 4 | 3 | 5 | 4 | 5 | 3 | 2 | — |
P/S ratio |
17.52 | 13.76 | 5.72 | 10.23 | 99.27 | 238.32 | 124.95 | 152.11 | 64.41 | 19.40 |
Altman Z-Score |
(6.97) | (4.37) | (2.17) | (0.09) | 12.54 | 17.79 | 11.87 | 6.34 | 2.33 | (0.48) |
Altman Z″-Score (non-manufacturers) |
(13.30) | (7.03) | (3.74) | (1.89) | 2.57 | 1.70 | 2.42 | 2.20 | (0.88) | 0.61 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
(4.01) | 3.03 | (3.75) | (1.00) | (1.82) | — | — | — | — | — |
P/Operating CF |
(4.99) | (6.75) | (9.91) | (13.06) | (78.86) | (362.53) | (52.26) | (65.43) | (24.67) | (11.31) |
P/B ratio |
0.56 | 0.59 | 0.99 | 2.03 | 8.17 | 19.49 | 5.45 | 4.49 | 3.43 | 1.17 |
Price to Tangible BV |
0.56 | 0.59 | 0.99 | 2.03 | 8.17 | 19.49 | 5.45 | 4.49 | 3.43 | 1.17 |
EV/Sales |
(9.61) | (4.99) | 1.12 | 5.94 | 88.66 | 223.70 | 106.41 | 112.84 | 45.29 | 0.91 |
EV/EBITDA |
0.46 | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.60 | 0.55 | (0.54) | (2.30) | (30.40) | (179.25) | (13.66) | (13.84) | (5.05) | (0.13) |
EV/FCF |
0.57 | 0.55 | (0.52) | (2.02) | (23.18) | (159.23) | (12.55) | (13.06) | (4.82) | (0.13) |
Quick Ratio |
5.67 | 7.34 | 8.11 | 4.16 | 7.68 | 5.71 | 7.96 | 7.39 | 9.14 | 6.07 |
Current Ratio |
5.79 | 7.58 | 8.48 | 4.40 | 7.79 | 5.78 | 8.17 | 7.53 | 9.29 | 6.14 |
Net Debt/EBITDA |
1.47 | 1.39 | 1.79 | 1.49 | 3.05 | 4.02 | 2.25 | 2.82 | 2.10 | 2.65 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.99% | 14.06% | 11.24% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.09 | 0.19 | 0.15 |
Asset Turnover |
0.02 | 0.03 | 0.10 | 0.12 | 0.07 | 0.07 | 0.04 | 0.03 | 0.04 | 0.05 |
Operating CF/Net income |
0.78 | 0.66 | 0.82 | 0.88 | 0.77 | 0.23 | 0.85 | 0.58 | 0.86 | 0.89 |
Capex/Depreciation |
(0.60) | (0.07) | (0.44) | (2.20) | (3.40) | (0.63) | (3.02) | (2.33) | (1.68) | (0.37) |
Interest Coverage |
— | — | — | (52.79) | (165.77) | (53.37) | (57.49) | (39.56) | (33.22) | (19.53) |
| (51.84%) | (54.21%) | (37.76%) | (48.46%) | (39.91%) | (55.11%) | (48.44%) | (56.05%) | (57.14%) | (60.19%) | |
| (35.89%) | (39.34%) | (26.56%) | (34.63%) | (27.48%) | (37.50%) | (38.09%) | (41.84%) | (42.88%) | (41.06%) | |
ROIC |
(2,617.38%) | (331.39%) | (223.64%) | (403.97%) | (215.52%) | 0.00% | (269.85%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(59.38%) | (58.62%) | (41.34%) | (56.57%) | (32.96%) | (39.31%) | (46.58%) | (36.38%) | (45.65%) | (41.98%) |
Average Days of Receivables |
50.31 | 94.76 | 10.49 | 145.85 | 56.70 | 64.04 | 0.00 | 38.50 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
1,622.46% | 990.40% | 271.66% | 332.77% | 385.92% | 399.64% | 821.82% | 1,181.94% | 836.78% | 600.91% |
Selling, General and Administrative Expense of Revenue |
699.98% | 544.12% | 128.20% | 87.47% | 102.64% | 107.83% | 221.32% | 333.50% | 289.16% | 225.19% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
375.02% | 304.42% | 68.40% | 81.76% | 97.35% | 97.83% | 163.01% | 132.76% | 87.82% | 72.33% |
Graham Net Nets |
0.83 | 0.91 | 0.53 | 0.28 | 0.07 | 0.03 | 0.13 | 0.21 | 0.28 | 0.84 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(117.35%) | (99.39%) | (44.44%) | (28.61%) | (3.81%) | (2.29%) | (7.31%) | (9.35%) | (16.19%) | (39.41%) |
Free Cash Flow Yield |
(95.93%) | (65.89%) | (38.12%) | (28.82%) | (3.85%) | (0.59%) | (6.79%) | (5.68%) | (14.57%) | (35.43%) |
Revenue per Share |
0.06 | 0.12 | 0.65 | 0.99 | 0.59 | 0.38 | 0.16 | 0.08 | 0.10 | 0.14 |
Operating CF per Share |
(0.89) | (1.08) | (1.34) | (2.56) | (1.72) | (0.48) | (1.22) | (0.69) | (0.88) | (0.94) |
Capex per Share |
(0.05) | (0.01) | (0.06) | (0.37) | (0.54) | (0.06) | (0.11) | (0.04) | (0.04) | (0.01) |
Free Cash Flow per Share |
(0.94) | (1.09) | (1.41) | (2.93) | (2.25) | (0.54) | (1.33) | (0.73) | (0.92) | (0.95) |
Cash per Share |
1.71 | 2.45 | 3.20 | 4.51 | 6.50 | 5.86 | 3.25 | 3.58 | 2.40 | 2.90 |
Shareholders Equity per Share |
1.74 | 2.80 | 3.74 | 5.00 | 7.16 | 4.67 | 3.59 | 2.86 | 1.84 | 2.30 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.74 | 2.80 | 3.74 | 5.00 | 7.16 | 4.67 | 3.59 | 2.86 | 1.84 | 2.30 |
Free Cash Flow |
(111.67) | (123.60) | (138.42) | (283.77) | (213.57) | (44.16) | (90.57) | (40.95) | (38.54) | (30.26) |
Working Capital |
172.63 | 253.39 | 292.45 | 388.02 | 552.13 | 408.76 | 199.28 | 177.93 | 91.55 | 78.14 |
Capital Expenditures |
(5.59) | (0.73) | (6.15) | (35.57) | (50.70) | (4.93) | (7.39) | (2.30) | (1.72) | (0.44) |
Net Current Asset Value |
96.95 | 169.94 | 193.74 | 280.45 | 390.80 | 256.31 | 169.57 | 152.63 | 74.49 | 71.43 |
EV/EBIT |
0.43 | 0.32 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.84 | 0.05 | 0.10 | 0.37 | 0.91 | 0.16 | 0.69 | 0.49 | 0.42 | 0.10 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.16 | 0.15 | 0.15 | 0.15 | 0.16 | 0.24 | 0.21 | 0.19 | 0.40 | 0.75 |
Cash ROIC |
(27.18%) | (20.68%) | (20.25%) | (30.84%) | (16.50%) | (5.09%) | (19.43%) | (10.88%) | (19.98%) | (17.20%) |
Accounts Receivable Turnover |
2.98 | 5.08 | 3.15 | 4.08 | 7.87 | 10.45 | 0.00 | 1.58 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
2.23 | 2.68 | 20.15 | 23.58 | 7.10 | 3.01 | — | 3.01 | — | — |
Average Payables |
6.01 | 7.04 | 6.49 | 8.44 | 7.45 | 6.05 | 5.01 | 2.94 | 1.31 | 0.97 |
Average Assets |
379.82 | 473.46 | 605.89 | 813.51 | 771.96 | 462.37 | 257.65 | 159.16 | 100.17 | 81.50 |
Average Common Equity |
262.95 | 343.57 | 426.17 | 581.39 | 531.64 | 314.60 | 202.61 | 118.83 | 75.17 | 55.59 |
Columns are period end dates